{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:59:59Z","timestamp":1791968399318,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00714-0","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T06:57:28Z","timestamp":1745996248000},"page":"1061-1082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High-Dose Steroids, Treatment Escalation, and Healthcare Burden in Myasthenia Gravis: A US Claims-Based Cohort Study"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1375-1028","authenticated-orcid":false,"given":"Mar","family":"Pujades-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Jedrzejczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Pilipczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00efs","family":"Taranc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"714_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-2-44","volume":"2","author":"VC Juel","year":"2007","unstructured":"Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"714_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16\u201322.","journal-title":"Neurohospitalist"},{"issue":"2","key":"714_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ncl.2018.01.004","volume":"36","author":"MH Rivner","year":"2018","unstructured":"Rivner MH, Pasnoor M, Dimachkie MM, Barohn RJ, Mei L. Muscle-specific tyrosine kinase and myasthenia gravis owing to other antibodies. Neurol Clin. 2018;36(2):293\u2013310.","journal-title":"Neurol Clin"},{"issue":"4","key":"714_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"2","key":"714_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. Neurol Clin. 2018;36(2):311\u201337.","journal-title":"Neurol Clin"},{"issue":"12","key":"714_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003432","volume":"17","author":"M Pujades-Rodr\u00edguez","year":"2020","unstructured":"Pujades-Rodr\u00edguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study. PLoS Med. 2020;17(12):e1003432.","journal-title":"PLoS Med"},{"issue":"1","key":"714_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001220","volume":"8","author":"J Wu","year":"2020","unstructured":"Wu J, Mackie SL, Pujades-Rodr\u00edguez M. Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis. BMJ Open Diabetes Res Care. 2020;8(1):e001220.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"25","key":"714_CR8","doi-asserted-by":"publisher","first-page":"E680","DOI":"10.1503\/cmaj.190178","volume":"191","author":"J Wu","year":"2019","unstructured":"Wu J, Keeley A, Mallen C, Morgan AW, Pujades-Rodr\u00edguez M. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ. 2019;191(25):E680\u2013E688.","journal-title":"CMAJ"},{"issue":"12","key":"714_CR9","doi-asserted-by":"publisher","first-page":"E295","DOI":"10.1503\/cmaj.191012","volume":"192","author":"TF Mebrahtu","year":"2020","unstructured":"Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodr\u00edguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. CMAJ. 2020;192(12):E295\u2013E301.","journal-title":"CMAJ"},{"issue":"5","key":"714_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1210\/er.2018-00097","volume":"39","author":"RS Hardy","year":"2018","unstructured":"Hardy RS, Zhou H, Seibel MJ, Cooper MS. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev. 2018;39(5):519\u201348.","journal-title":"Endocr Rev"},{"issue":"4","key":"714_CR11","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s11481-021-10004-9","volume":"16","author":"S Jacob","year":"2021","unstructured":"Jacob S, Mazibrada G, Irani SR, Jacob A, Yudina A. The role of plasma exchange in the treatment of refractory autoimmune neurological diseases: a narrative review. J Neuroimmune Pharmacol. 2021;16(4):806\u201317.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"3","key":"714_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"key":"714_CR13","unstructured":"Ultomiris US PI. Available from https:\/\/alexion.com\/documents\/ultomiris_uspi. Accessed Jan 2025."},{"key":"714_CR14","unstructured":"Soliris US PI. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125166s422lbl.pdf. Accessed Jan 2025."},{"key":"714_CR15","unstructured":"VYVGART US PI. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761304s000lbl.pdf. Accessed Jan 2025."},{"key":"714_CR16","unstructured":"Rystiggo US PI. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761286s000lbl.pdf. Accessed Jan 2025."},{"issue":"5","key":"714_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive Phase 3 study. Lancet Neurol. 2023;22(5):383\u201394.","journal-title":"Lancet Neurol"},{"key":"714_CR18","unstructured":"UCB announces U.S. FDA approval of ZILBRYSQ[\u00ae] (zilucoplan) for the treatment of adults with generalized myasthenia gravis: UCB Pharma. Available from https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-US-FDA-approval-of-ZILBRYSQR-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis. Accessed Jan 2025."},{"key":"714_CR19","unstructured":"UCB announces approval of RYSTIGGO[\u00ae] (rozanolixizumab) and ZILBRYSQ[\u00ae] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan: UCB Pharma. Available from https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-approval-of-RYSTIGGOR-rozanolixizumab-and-ZILBRYSQR-zilucoplan-for-the-treatment-of-adult-patients-with-generalized-myasthenia-gravis-in-Japan. Accessed Jan 2025."},{"key":"714_CR20","unstructured":"Rystiggo Japan PI. Available from https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/820110_63994A9A1022_1_01. Accessed Jan 2025."},{"key":"714_CR21","unstructured":"Ultomiris approved in Japan for the treatment of adults with generalised myasthenia gravis: AstraZeneca. Available from https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/ultomiris-approved-in-japan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis.html. Accessed Jan 2025."},{"issue":"3","key":"714_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Efgartigimod: first approval. Drugs. 2022;82(3):341\u20138.","journal-title":"Drugs"},{"key":"714_CR23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fneur.2020.00538","volume":"11","author":"D Menon","year":"2020","unstructured":"Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis. Front Neurol. 2020;11:538.","journal-title":"Front Neurol"},{"issue":"7","key":"714_CR24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M, Miljkovi\u0107 MD, Chahin N, Sahagian G, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised Phase 1b\/2a study. Lancet Neurol. 2023;22(7):578\u201390.","journal-title":"Lancet Neurol"},{"key":"714_CR25","unstructured":"Glucocorticoid therapy: BNF NICE. Available from https:\/\/bnf.nice.org.uk\/treatment-summaries\/glucocorticoid-therapy\/. Accessed Jan 2025."},{"key":"714_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26104","author":"I Lee","year":"2018","unstructured":"Lee I, Kaminski HJ, Xin H, Cutter G. Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry. Muscle Nerve. 2018. https:\/\/doi.org\/10.1002\/mus.26104.","journal-title":"Muscle Nerve"},{"issue":"7","key":"714_CR27","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s10072-024-07368-0","volume":"45","author":"V Di Stefano","year":"2024","unstructured":"Di Stefano V, Iacono S, Militello M, Leone O, Rispoli MG, Ferri L, et al. Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients. Neurol Sci. 2024;45(7):3481\u201394.","journal-title":"Neurol Sci"},{"key":"714_CR28","doi-asserted-by":"publisher","first-page":"175628642211503","DOI":"10.1177\/17562864221150327","volume":"16","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A. Healthcare resource use in myasthenia gravis: a US health claims analysis. Ther Adv Neurol Disord. 2023;16:17562864221150327.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"714_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/mus.27791","volume":"67","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A. Treatment patterns in myasthenia gravis: a United States health claims analysis. Muscle Nerve. 2023;67(4):297\u2013305.","journal-title":"Muscle Nerve"},{"key":"714_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120531","volume":"445","author":"A Ting","year":"2023","unstructured":"Ting A, Story T, Lecomte C, Estrin A, Syed S, Lee E. A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment. J Neurol Sci. 2023;445:120531.","journal-title":"J Neurol Sci"},{"issue":"3","key":"714_CR31","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3988\/jcn.2019.15.3.376","volume":"15","author":"H Xin","year":"2019","unstructured":"Xin H, Harris LA, Aban IB, Cutter G. Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a Myasthenia Gravis Foundation of America patient registry sample. J Clin Neurol. 2019;15(3):376\u201385.","journal-title":"J Clin Neurol"},{"key":"714_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1415","volume":"357","author":"AK Waljee","year":"2017","unstructured":"Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.","journal-title":"BMJ"},{"issue":"4","key":"714_CR33","doi-asserted-by":"publisher","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","volume":"52","author":"T Volmer","year":"2018","unstructured":"Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703.","journal-title":"Eur Respir J"},{"issue":"1","key":"714_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5588\/ijtld.12.0260","volume":"17","author":"SM Ou","year":"2013","unstructured":"Ou SM, Liu CJ, Chang YS, Hu YW, Chao PW, Chen TJ, et al. Tuberculosis in myasthenia gravis. Int J Tuberc Lung Dis. 2013;17(1):79\u201384.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5\u20136","key":"714_CR35","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010;43(5\u20136):428\u201335.","journal-title":"Autoimmunity"},{"key":"714_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116648","volume":"410","author":"J Morren","year":"2020","unstructured":"Morren J, Li Y. Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci. 2020;410:116648.","journal-title":"J Neurol Sci"},{"issue":"2","key":"714_CR37","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11239-021-02610-4","volume":"53","author":"EM Ammann","year":"2022","unstructured":"Ammann EM, Chrischilles EA, Carnahan RM, Fireman B, Fuller CC, Schweizer ML, et al. Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006\u20132012). J Thromb Thrombolysis. 2022;53(2):264\u201372.","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"714_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/mus.26884","volume":"62","author":"PH Jin","year":"2020","unstructured":"Jin PH, Shin SC, Dhamoon MS. Risk of thrombotic events after inpatient intravenous immunoglobulin or plasma exchange for neurologic disease: a case-crossover study. Muscle Nerve. 2020;62(3):327\u201332.","journal-title":"Muscle Nerve"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00714-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00714-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00714-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:58:23Z","timestamp":1747663103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00714-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["714"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00714-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mar Pujades-Rodr\u00edguez, Jiachen Zhou and Tha\u00efs Taranc\u00f3n are employees and shareholders of UCB. Adam Jedrzejczyk and Olga Pilipczuk are contractors for UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. UCB holds a license to use the data from both Merative\u2122 MarketScan\u00ae research databases for research and publish the derived results. Because the databases used in this study consist of de-identified data compliant with the US Health Insurance Portability and Accountability Act of 1996, no ethics committee approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}